Sulforaphane for Autistic Disorder

Attentional problems are present in more than half of those referred to ASHA clinics and about half of those assessed by clinicians and therapists working in community clinics have autistic spectrum disorders, which make up a considerable number of diagnoses.

Parents should know that any purported cure for autism must be medically discredited as pseudoscientific, and medical treatment is not going to change the core, enduring issues in a child with autism.

The overall effect of autism spectrum disorder is greater than the combined contribution of genetics and the environment. Thus, both genetic and environmental factors are involved in its development and presentation. However, the genes for autism are not fully understood. What is known about the genetics of ASDs is mostly based on a sample of single-gene, high-risk models in which the children had autistic symptoms. For example, the S-protein receptor (SORL1) is one gene that has been discussed as being involved in ASDs. Sorl1 is thought to play a role in the development of communication and social skills, and in particular in understanding facial expressions.

An estimated 1.3 million children and adults in the United States have autism spectrum disorder. The number of patients with autism spectrum disorder will not be known until the last decade of the 21st century.

The prevalence of ASD is high and treatments for ASD are complex. There is scope for new approaches to treatment as ASD is known to have a number of possible treatments and symptomatology.

This paper describes the most common signs, and describes signs that occur in only a minority of patients. Some signs may occur in patients without any autistic symptoms, and these signs can appear for a longer period in this cohort than in the previous reports. In addition, some of the symptoms have a delay in onset that is longer than would be expected. Children with ASDs may have both symptoms of ASD and nonspecific cognitive symptoms, which affect their school readiness. Children with ASDs have a risk of poor social development, emotional disturbances, or social difficulties.

The presence of Sulforaphane in plants is associated with decreased neurochemical effects, and it has improved quality of life in those with ASD. Longitudinal research is needed to determine whether the presence of Sulforaphane may decrease neurobehavioral symptoms in individuals with ASD.

Results from three meta-analyses suggest that a higher frequency of trials is required among clinical trial registrants in order to assess the efficacy of autistic disorder agents systematically.

The use of SFN in the treatment of autism was based on case reports and experience with other diseases. There have been few randomized controlled trials done on this drug. Therefore, [it is difficult, if not impossible to generalize from case reports to a clinical situation]] to conclude that SFN is an effective treatment in autism.

Based upon our data, we suggest that the average age of diagnosis of ASD is 8 years. This estimate is likely to be an under-estimate given that we did not investigate cases presenting before age 4. More studies are needed to further study this topic.

There was no evidence of a familial aggregation in the current study, which suggests that the genetic predisposition to autism cannot be determined by looking at families in isolation. It may be of interest to study the genetic predisposition to ASD in the setting of other psychiatric disorders. (Trial registration number: ACTRN1258001062699.